essentially as previously described (Gregorieff et al 2005) . For immunofluorescence studies, antigen retrieval was performed at high pressure for 5 minutes in 10mM sodium citrate buffer pH 6.0 containing 0.05% tween-20, blocked with mouse-on-mouse block (Vector labs) for 1 hour, washed twice with wash buffer (PBS, 0.5% Triton X-100), blocked with 2.5% normal goat serum (in wash buffer) and incubated overnight with primary antibodies diluted in wash buffer at 4°C. Slides were washed three times prior to incubation with Alexa-fluor conjugated secondary antibodies for 1 hour at room temperature. Slides were washed three times, nuclei counterstained with DAPI (1µg/mL) and mounted with ProLong Gold mounting medium (Life Technologies). The following antibodies were used: anti-Brd4 (Bethyl Labs, A301-985A100, 1:100), anti-E-cadherin (Transduction labs C20820, 1:250), anti-GFP (Abcam Ab13970, 1:500), Alexa-fluor-anti-mouse-IgG, anti-rabbit-IgG and anti-chicken IgG (Life technologies, 1:1000).
H&E and immunostained tissue sections were imaged on a Zeiss Axio Imager Z.2 using 10x (NA 0.3), 20x (NA 0.5) objectives, coupled with a Hamamatsu CCD camera.
Intestinal damage
For intestinal challenge experiments, shBrd4 and shRen mice were treated with doxycycline for 2 weeks, then either treated with a single dose of 9Gy ionizing radiation, or given a single dose of Adriamycin (doxorubicin hydrochloride) 10mg/kg by intraperitoneal injection.
JQ1 preparation and administration
JQ1 powder was dissolved in DMSO to generate a concentrated 50mg/mL stock solution. For administration to animals, a working solution was generated by diluting 1 part of the concentrated JQ1 stock drop-wise into 9 parts 10% Hydroxypropyl beta cyclodextrin (Sigma C0926). C57Bl/6 mice received once daily intraperitoneal injections of 100mg/kg JQ1 for 2 weeks. Ex-vivo, JQ1 was added to crypt growth medium to a final concentration of 100nM. Doxycycline was added to crypt growth medium to a final concentration of 0.5µg/mL.
Intestine crypt isolation and culture:
Under sterile conditions, the anterior 15cm of mouse small intestine was isolated, opened longitudinally and washed extensively in ice-cold phosphate buffered saline (PBS) to remove intestinal contents. ~5mm lengths of 'clean' intestine were cut, placed in ice-cold sterile-filtered PBS/5mM EDTA, and villi released by vigorous pipetting. Villi-containing supernatant was discarded. Intestine pieces were first incubated with PBS/5mM EDTA on ice for 10 minutes, and again for 30 minutes, with villi released by inversion at the end of each EDTA/PBS incubation. Intestine pieces were washed once with PBS, and crypts released into 10mL PBS by vigorous pipetting. 10mL crypt isolation medium [DMEM/F12 Advanced (Life Technologies), 100U/mL penicillin, 100µg/mL streptomycin (Life Technologies), 1x Glutamax (Life Technologies)] was added to released crypts, and passed through 100µm filter. The crypt-containing solution was next passed through a 70µm filter into a tube pre-coated with sterile 10% (w/v) bovineserum albumin. Crypts were centrifuged at 150g for 5 minutes and resuspended in crypt growth media [DMEM/F12 Advanced, 100U/mL penicillin, 100µg/mL streptomycin, 1x glutamax, 40ng/mL murine recombinant epidermal growth factor (Peprotech #315-09), 50ng/mL murine recombinant Noggin (Peprotech #250-38) and 250ng/mL R-spondin (R&D systems, 3475-RS)]. Crypts were suspended in Matrigel basic membrane matrix (BD #354234), covered with crypt growth medium and incubated at 37°C, 5% CO 2 . For determination of organoid forming efficiency, freshly isolated crypts were plated in triplicate and assessed 12 hours later to count viable crypts. The same microscopic fields were examined at day 4 and the data were normalized as relative crypt forming efficiencies (proliferative organoids at day 4 / viable crypts at 12hrs). 
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